BREAKING NEWS
We’re excited to share that our partnership with New York Kidney & Hypertension Medicine (NYKHM) is expanding through a multi-tiered approach to slow the progression of kidney disease in Queens, Brooklyn and the greater NY metropolitan area, communities that have a higher prevalence of both type 2 diabetes, and correspondingly, chronic kidney disease.
- NYKHM will expand the use of kidneyintelX.dkd blood testing in its underserved, high-risk communities, and patient population.
NYKHM became an advocate for the test in January 2024 to improve overall patient health outcomes by mitigating the progressive decline in kidney function within its type 2 diabetic patients with early-stage chronic kidney disease.
The initiative is expected to increase immediate access to thousands of patients for the kidneyintelX.dkd test, which is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment.
- Starting in May, NYKHM also introduced, and is helping educate and support kidneyintelX.dkd test rollouts within primary care groups that it already works with throughout the city. These rollouts are expected to be ongoing in 2025 and 2026.
- Later in 2025, we plan to launch our first patient-oriented community campaign to increase awareness of chronic kidney disease risk factors, and the importance of proactive management.
We’re proud to further our collaboration with NYKHM and with Dr. Premila Bhat, Partner, NYKHM and Managing Partner, Tidal Dialysis, LLC, who has has said: “We are dedicated to bringing the latest medical innovations to our communities, so our patients with chronic kidney disease can take charge of their health and wellness. The kidneyintelX.dkd test enables both physicians and patients to understand kidney disease risk early, so we can take timely action and deliver the most effective care available today.”
